Nedd4L expression is downregulated in prostate cancer compared to benign prostatic hyperplasia
X.Y. Hu,Y.M. Xu,Q. Fu,J.J. Yu,J. Huang
DOI: https://doi.org/10.1016/j.ejso.2008.09.015
2009-01-01
European Journal of Surgical Oncology (EJSO)
Abstract:Results Nedd4L ( P < 0.001) expressions were significantly decreased in PC compared to benign prostate tissue. Furthermore, downregulation of Nedd4L ( P < 0.05) expression correlated with increasing Gleason score. Conclusions These data suggest that prostate cancer cells in vivo may need Nedd4L expression to regulate TGF-β1 signaling, and that Nedd4L expression might be involved in prostate cancer development. Keywords Prostate cancer Nedd4-2 Nedd4L TGF-β1 Introduction Prostate cancer (PC) is a commonly diagnosed cancer and a major cause of cancer death in old men. 1,2 Despite the prevalence of this disease, the precise mechanisms involved in prostate carcinogenesis and progression remains uncertain. It is likely that the transition from normal to malignant prostate epithelial cells involves a number of genetic alterations in several different molecular pathways regulating normal cell proliferation and differentiation. 3 As has been the case in other cancers such as breast and non-Hodgkin's lymphoma, it is hoped that a better understanding of the biology of the cancer will lead to new treatments and biological markers of outcome. 4,5 TGF-β1 is the most important isoforms of TGF-β peptides in mammal which is involved in a variety of biological processes, including regulation of cell growth, angiogenesis, immune response, and modulation of extracellular matrix (ECM). 6 TGF-β1 mediates its effect by binding to transmembrane protein receptors, then transducing signal from the cytoplasm to the nucleus by a family of proteins known as Smads. In prostate cancer, TGF-β1 can promote prostate cancer growth by inhibiting immune response against the tumor, and by stimulating angiogenesis and metastasis. 7 Therefore, investigation into the TGF-β system in prostate cancer is needed in order to learn if this system can be manipulated for therapeutic purposes. Recently, Nedd4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) was identified as a novel protein which could inhibit TGF-β signaling in TGF-β receptors and Smads levels. 8 Nedd4L is the human homologue of mouse Nedd4-2. 9 However, the expression status of Nedd4L in prostate tissues is not well known. The aim of this study was to define the pattern of Nedd4L protein expression in the hyperplastic and malignant human prostate tissue and to determine whether differences in expression were associated with disease development. Materials and methods Patient population A cohort of archival formalin-fixed, paraffin embedded specimens ( n = 56) was obtained from patients treated with radical prostatectomy (RP) for localized PC at Shanghai Jiaotong University Affiliated 6th People's Hospital, Shanghai (mean age 67 years, range 47–73 years). All surgery was performed by one of the four urologists and the radical prostatectomy product was analyzed by a pathologist. Patients who received neoadjuvant hormonal therapy were excluded from the study. In addition, paraffin embedded tissues were obtained from 31 patients with benign prostatic hyperplasia (mean age 66 years, range 56–78 years) at the time of transurethral resection. Tissue microarray construction Using the technique of Kononen et al. 10 mediumdensity tissue microarrays were constructed using tissue core biopsies of 1.5 or 2 mm. Hematoxylin and eosin stained template sections of the RP paraffin donor blocks were marked up for areas of nodular hyperplasia and PC by a histopathologist according to accepted criteria. 11 Each patient case was represented by a mean of three biopsies (range 2–5 biopsies) of PC representative of the primary, secondary, and tertiary Gleason scores and one biopsy of nodular hyperplasia adjacent to cancer. In total, 243 elements representing 56 patients were placed in 5 tissue microarrays (178 PC, 65 nodular hyperplasia adjacent to cancer). Verification of the pathology of each tissue element was performed by a histopathologist. BPH cases were assessed using conventional sections. All tissue was serially sectioned at 4 μm and mounted on adhesion slides [Maixin, China]. Immunohistochemistry Nedd4L proteins were detected using antibodies produced from rabbit according to the description in Refs. 12,13 The anti-Nedd4L antibody was a rabbit polyclonal antibody raised against a peptide mapping to the amino terminus of Nedd4L. The specificity of Nedd4L was confirmed by Western blotting and showed single specific band. The sections were dewaxed and rehydrated prior to unmasking in citrate/EDTA target retrieval solution, pH 6.0. The sections were initially quenched with 3% H 2 O 2 , incubated with avidin and biotin block (DAKO, Carpinteria, CA) for 10 min each and subsequently, for 30 min with either anti-Nedd4L antibody 1:50 followed by 15 min incubation with 1:200 biotinylated horse anti-rabbit antibody (Vector laboratories, Burlingame, CA). Astreptavidin–biotin peroxidase detection system was used according to the manufacturer's instructions (Vecta-stain Elite kit, Vector laboratories). A detection system using 3,3'-diaminobenzidine as substrate (DAKO) was subsequently used, followed by counterstaining using hematoxylin (DAKO). Assessment of immunohistochemistry Immunostaining was initially assessed by one histopathologist and subsequently reviewed independently by another histopathologist. Both individuals were blinded to patient outcome. Nedd4L staining was observed in the cytoplasm. Cytoplasmic expression was assessed according to an intensity scale as negative, week, moderate or strong. 13,14 This procedure was repeated for areas of hyperplasia adjacent to cancer. Conventional sections of BPH were scored using the same method with assessment of a number of randomly selected areas of each section. As negative controls, a slide was treated by replacement of primary antibody with non-immune serum. Negative staining was defined as an absence of expression at a magnification of ×400. All discrepancies in scoring were reviewed and a consensus reached. Statistical analysis Differences in the proportion of patients with different cytoplasmic levels of Nedd4L expression in the various pathologies were tested using the Chi-squared test. The correlation between Nedd4L expression and Gleason score was assessed using the Chi-squared test. A P -value of <0.05 was required for significance. All reported P -values are two sided. All statistical analyses were performed using SPSS 14.0 (Statistical Program for Social Sciences) software (SPSS Inc, Chicago, CA). Results Nedd4L expression in benign and malignant prostate tissue All types of prostate tissue demonstrated granular cytoplasmic expression of Nedd4L in epithelial cells. The majority of BPH ( Fig. 1 a ) cases had strong Nedd4L expression. The hyperplastic lesions adjacent to PC also had a greater distribution of expression, 73% had moderate–strong expression ( Table 1 ). In contrast, only 4 cases of 56 samples had strong expression ( Fig. 1 b). Similarly, assessment of paired pathology (i.e. hyperplasia and cancer from the same patient) demonstrated that Nedd4L expression appeared to be downregulated in 65% of PC samples. Furthermore, of the 56 PC cases, 25 had no expression of Nedd4L ( Fig. 1 d). Chi-squared tests demonstrated a significant decrease in Nedd4L expression in PCs compared to BPH ( P < 0.001) and hyperplasia adjacent to cancer ( P < 0.001). Correlation of Nedd4L expression with gleason score Loss of Nedd4L expression in PCs correlated with Gleason score ( P = 0.010) with a higher percentage of cancers negative for Nedd4L as Gleason score increased ( Table 2 ). In those cancers with a Gleason score of ≥8, 86% were Nedd4L negative. Discussion Nedd4-2 is a novel negative factor in TGF-β1 signaling Nedd4-2 and a structurally related protein, Nedd4, have been shown to interact with the epithelial sodium channel, and to down-regulate its activity via the ubiquitin–proteasome pathway. 15,16 The epithelial Na+ channel (ENaC) plays a fundamental role in the control of the whole body Na+ balance and consequently regulation of blood volume and pressure. 17 It is expressed in the apical membrane of segment-specific cells of the aldosterone-sensitive distal nephron, 18 and facilitates the entry of Na+ in the cell. The cell surface expression of ENaC appears to be tightly regulated, both by clathrin-dependant endocytosis 19,20 and by ubiquitination via the ubiquitin-protein ligase Nedd4, its closely related isoform Nedd4-2, and/or WWP2 (WW-domain containing protein). Ubiquitination (also referred to as ubiquitylation) involves an enzymatic cascade including the ubiquitin-activating enzyme E1, ubiquitin-conjugating (or ubiquitin-carrier) enzyme E2, and ubiquitin-protein ligase E3, the latter being involved in substrate recognition. Recently, Nedd4-2 was identified as a novel negative factor in TGF-β1 signaling, which was identified previously as E3 ubiquitin ligases for R-Smads and TGF-β superfamily receptors. Nedd4-2 associates with TGF-β type I receptor via Smad7, and induces its ubiquitin-dependent degradation. Moreover, Nedd4-2 bound to TGF-β-specific R-Smads, Smads 2 and 3, in a ligand-dependent manner, and induced degradation of Smad2, but not Smad3. 8 During carcinogenesis, a change in the balance between proliferation, differentiation, and apoptosis occurs in favor of proliferation. Homeostasis in the prostate is maintained by the interplay of factors, which directly or indirectly regulate cell growth, differentiation and apoptosis. TGF-β1 was thought to have positive effect on prostate carcinogenesis which mediates its effects on target cells by forming a heteromeric complex with ligand-specific transmembrane serine–threonine kinase receptors. 21,22 Activated TGFβ-R phosphorylates the Smad proteins that, on activation, associate with the common mediator Smad4. The complex then translocates to the nucleus where it, alone or in complex with other nuclear factors, initiates or represses gene transcription. 23,24 Therefore, Smads and TGF-β1 receptor are two very important sections of TGF-β1 signaling. As Nedd4-2 can modulate TGF-β1 signaling, the expression status of it might play a pivotal role in prostate cancer aggressiveness and/or progression. Nedd4-2 (Nedd4L) expression in prostate cancer and benign prostatic hyperplasia tissue To date, several reports have described Nedd4-2 mRNA expression in cancer cell lines. 8,23 Although Nedd4-2 mRNA is widely expressed in the cancer cell lines, the intensity of Nedd4-2 expression was cell-type specific. 8,25–27 Nedd4L is the human homologue of mouse Nedd4-2 which was identified on human chromosome 18q21 and has several transcripts. 19,26,27 Some of Nedd4L transcripts were detected at high levels in human prostate and mammary gland, moreover, androgens can differentially regulate the expression of Nedd4L transcripts in LNCaP human prostate cancer cells. 27 However, the role of Nedd4L protein in normal prostate growth and development is poorly understood. The data in our study point to expression of Nedd4L is downregulated in PC compared to benign prostatic hyperplasia tissue. As Nedd4L could inhibit TGF-β signaling in TGF-β receptors and Smads levels, 8 downregulation of Nedd4L in PC might associate with TGF-β1 inducing prostate cancer growth. 7 Correlation of Nedd4L expression with Gleason score Gleason system is the most commonly used histologic grading system for prostate cancer to help predict pathologic stage and prognosis, which has been shown to correlate directly with pathologic extent of disease. Our research demonstrated that decreased expression of Nedd4L in PCs with higher Gleason score is consistent with the in vitro data. Loss of the growth inhibitory effect of Nedd4L in higher grade cancers could contribute to their more aggressive phenotype. Decreased Nedd4L expression correlated with increasing Gleason score of PC cases, suggesting downregulation of these molecules is related to progression to a more aggressive form of PC. Conclusions The data provided in the current study define for the first time the in vivo patterns of Nedd4L expression in prostate cancers. The expression of Nedd4L is decreased in the progression to prostatic malignancy, with loss of Nedd4L expression correlating with increasing Gleason score. These data suggested that regulation of Nedd4L expression might play a role in the development of prostate cancers, the decreased levels of Nedd4L in PC and in particular in more aggressive cancers suggest downregulation of Nedd4L expression related to control of cell proliferation. As yet there is a paucity of information as to what is happening at a cellular level to Nedd4L signaling, a better understanding of the mechanisms underlying the association of Nedd4L with its interplay molecular in prostate cancer progression could potentially lead to more effective clinical management, as well as provide new target pathways for prostate cancer therapy. Conflict of interest All authors have made a substantial contribution to the text submitted for publication; all have read and approved the final manuscript. All authors have no substantial direct or indirect commercial or financial incentive associated with publishing the article. Acknowledgements We thank Dr Huang Jing for his pathological knowledge and excellent technical assistance. We also thank the Postdoctoral Foundation of China (20060400651). References 1 E.A. Tracey R. Supramaniam Cancer in New South Wales Incidence and mortality 2000 featuring projections to 2010 for selected sites 2002 The Cancer Council NSW Sydney 2 A. Jemal R. Siegel E. Ward T. Murray J. Xu M.J. Thun Cancer statistics, 2007 CA Cancer J Clin 57 2007 43 66 3 S. Nagrath L.V. Sequist S. Maheswaran Isolation of rare circulating tumour cells in cancer patients by microchip technology Nature 450 2007 1235 1239 4 P. McLaughlin A.J. Grillo-Lopez B.K. Link R. Levy M.S. Czuczman M.E. Williams Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 16 1998 2825 2833 5 D.J. Slamon B. Leyland-Jones S. Shak H. Fuchs V. Paton A. Bajamonde Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2 N Engl J Med 344 2001 783 792 6 L. Wyatt C. Wadham L.A. Crocker M. Lardelli Y. Khew-Goodall The protein tyrosine phosphatase Pez regulates TGFbeta, epithelial-mesenchymal transition, and organ development J Cell Biol 178 2007 1223 1235 7 Q. Zheng A. Safina A.V. Bakin Role of high-molecular weight tropomyosins in TGF-beta-mediated control of cell motility Int J Cancer 122 2008 78 90 8 G. Kuratomi A. Komuro K. Goto Nedd4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF-β (transforming growth factor-β) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-β type I receptor Biochem J 386 2005 461 470 9 H. Chen C.A. Ross N. Wang Nedd4L on human chromosome 18q21 has multiple forms of transcripts and is a homologue of the mouse Nedd4-2 gene Eur J Hum Genet 9 2001 922 930 10 J. Kononen L. Bubendorf A. Kallioniemi M. Barlund P. Schraml S. Leighton Tissue microarrays for high-throughput molecular profiling of tumor specimens Nat Med 4 1998 844 847 11 J.E. McNeal Prostate S.S. Sternberg Histology for pathologists 1997 Lippincott-Raven Philadelphia/New York 997 1018 12 F. Fouladkou R. Alikhani-Koopaei B. Vogt A naturally occurring human Nedd4–2 variant displays impaired ENaC regulation in Xenopus laevis oocytes Am J Physiol Renal Physiol 287 2004 F550 F561 13 A.V. Biankin A.L. Morey C.S. Lee DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma J Clin Oncol 20 2002 4531 4542 14 S.M. Henshall D.E.H. Afar K.K. Rasiah Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer Oncogene 22 2003 6005 6012 15 E. Kamynina C. Debonneville M. Bens A. Vandewalle O. Staub A novel mouse Nedd4 protein suppresses the activity of the epithelial Na1 channel FEBS Lett 15 2001 204 214 16 R. Zhou S.V. Patel P.M. Snyder Nedd4-2 catalyzes ubiquitination and degradation of cell surface ENaC J Biol Chem 282 2007 20207 20212 17 D. Wiemuth Y. Ke M. Rohlfs F.J. McDonald Epithelial sodium channel (ENaC) is multi-ubiquitinated at the cell surface Biochem J 405 2007 147 155 18 J. Loffing L. Pietri F. Aregger Differential subcellular localization of ENaC subunits in mouse kidney in response to high- and low-Na diets Am J Physiol Renal Physiol 279 2000 F252 F258 19 J. Ekberg F. Schuetz N.A. Boase Regulation of the voltage-gated K(+) channels KCNQ2/3 and KCNQ3/5 by ubiquitination. Novel role for Nedd4-2 J Biol Chem 282 2007 12135 12142 20 P.M. Snyder M.P. Price F.J. McDonald Mechanism by which Liddle's syndrome mutations increase activity of a human epithelial Na+ channel Cell 83 1995 969 978 21 S.F. Shariat M. Shalev A. Menesses-Diaz Preoperative plasma levels of transforming growth factor beta (1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy J Clin Oncol 19 2001 2856 2864 22 B. Zhu K. Fukada H. Zhu N. Kyprianou Prohibitin and cofilin are intracellular effectors of transforming growth factor beta signaling in human prostate cancer cells Cancer Res 66 2006 8640 8647 23 M. Wan Y. Tang E.M. Tytler Smad4 protein stability is regulated by ubiquitin ligase SCF β-TrCP1 J Biol Chem 279 2004 14484 14487 24 X. Lin M. Liang X.H. Feng Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-β signaling J Biol Chem 275 2000 36818 36822 25 A. Komuro T. Imamura M. Saitoh1 Negative regulation of transforming growth factor-b (TGF-b) signaling by WW domain-containing protein 1 (WWP1) Oncogene 23 2004 6914 6923 26 I.H. Lee A. Dinudom A. Sanchez-Perez S. Kumar D.I. Cook Akt mediates the effect of insulin on epithelial sodium channels by inhibiting Nedd4-2 J Biol Chem 282 2007 29866 29873 27 H. Qi J. Grenier A. Fournier C. Labrie Androgens differentially regulate the expression of NEDD4L transcripts in LNCaP human prostate cancer cells Mol Cell Endocrinol 210 2003 51 62